Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etirinotecan pegol versus physician's choice chemotherapy in metastatic breast cancer with stable brain metastases
MOH_2017-03-13_000227Phase 3Recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of crizanlizumab in breast cancer (2 arms), sponsored by Nektar Therapeutics. Started Mar 2017; status: recruiting.
02
Drugs
crizanlizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-03-13_000227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-13_000227.